Pembrolizumab? For triple negative breast cancer, NICE says go back to the lab

In a decision made by NICE (London, UK), the use of pembrolizumab plus chemotherapy will not be recommended to treat triple negative breast cancer. This is despite evidence suggesting that the treatment is more effective than treatments already recommended by NICE, including paclitaxel or nab-paclitaxel. However, the long-term benefits of the pembrolizumab and chemotherapy combination are uncertain. Pembrolizumab – also known by its brand name Ketruda® – is given to patients every 3 weeks through an injection. It is an immunotherapy specifically for triple negative breast cancer and blocks the activity of the protein PD-L1. The protein has been noted...